The peptides and macrocycle drug discovery services market is estimated to be worth USD 1.5 billion in 2030

Drug discovery is challenging and involves several complexities. In order to continue to add new molecules their pipelines, drug developers are opting to outsource such operations to contract research organizations (CROs). Outsourcing of peptides and macrocycle drug discovery has emerged as one of the recent trends in the overall pharmaceutical domain.

Roots Analysis has announced the addition of “Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020-2030” report to its list of offerings.

The report features an extensive study on the current market landscape and future of companies offering services for peptide therapeutics and macrocycle drug discovery operations. The study includes in-depth analyses, highlighting the capabilities of various service / technology providers engaged in this market. Amongst other elements, the report includes:

Key Market Insights

More than 35 industry players claim to offer services for the identification, characterization and development of peptides and macrocycle-based pharmacological lead candidates
Several technology developers have made significant contributions in terms of developing novel platforms, based on a variety of innovative approaches, for the discovery of peptide-based drugs and macrocyclic molecules.
A detailed assessment of the current market landscape of companies offering peptide and macrocycle drug discovery services
An insightful geographical benchmarking of the capabilities of companies of various sizes, highlighting the key focus areas, comparing their existing strengths both within and beyond their respective peer groups (based on geography and company size).

An in-depth analysis of peptide platform and library service providers, featuring information on their company details, purpose of the platform, type of synthetic peptides manufactured and platform access model.

To order this 180+ page report, which features 90+ figures and 85+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/peptides-and-macrocycle-discovery/300.html

The USD 1.5 billion (by 2030) financial opportunity within the peptides and macrocycles drug discovery service and platform providers market has been analyzed across the following segments:

Type of peptides
Synthetic peptides
Biologic and recombinant peptides

Type of discovery steps
Target identification and validation
Hit identification
Lead generation
Lead optimization

Therapeutic Area
Oncological disorders
Metabolic disorders
Cardiovascular disorders
Infectious diseases
Urological disorders
Endocrine disorders
CNS disorders
Other diseases

Company Size
Small companies
Mid-sized companies
Large and very large companies

Key geographical regions

Europe
North America
Asia-Pacific and the Rest of the World

The report features inputs from eminent industry stakeholders, according to whom peptide and macrocycles drug discovery outsourcing market is continuously pacing up. The report includes detailed transcripts of discussions held with the following experts:

Mark I Peterson (CEO, Cyclenium Pharma)
Jan Hoflack (Chief Scientific Officer, Head of Biotech Business Unit, Oncodesign)

The research covers profiles of key players that offer peptides and macrocyclic drugs discovery platforms and services, featuring an overview of the company, its service portfolio / technology platform, and an informed future outlook.